Tyrosine kinase inhibitors (TKIs) are anti‐cancer drugs that target tyrosine kinases, enzymes
that are involved in multiple cellular processes. Currently, multiple oral TKIs have been …

Highlights•Complete overview on exposure–response relationships for TKIs used in solid
tumors.•Dose individualization is expected to minimize toxicity and improve efficacy.•For …

Onco-nephrology is a new and evolving subspecialized area in nephrology that deals with
kidney diseases in cancer patients. As many newer cancer therapies emerge in the field of …

Aims: Sine efficiency of tyrosine kinase inhibitor (TKI) therapy in dialyzed patients is still
unclear we aim to analyze the outcome of treatment in such cohort. Patients & methods: We …

Background Patients with severe renal impairment or undergoing hemodialysis are usually
excluded from clinical trials. Available data regarding safety and activity of systemic …

Background Patients with metastatic renal cell carcinoma (mRCC) with renal insufficiency
are generally excluded from clinical trials, despite their increasing numbers. Thus, we …

The increasing availability of novel biological anticancer agents has greatly improved the
outcome of several cancer patients; unfortunately, data regarding efficacy, safety and …

Axitinib is approved with indication in patients with advanced renal cell carcinoma (RCC).
Due to the localization of this cancer, physicians sometimes have to deal with hemodialyzed …

Aims: New chemotherapeutic agents prolong survival of patients with pancreatic ductal
adenocarcinoma (PDAC). Although their incidence is rising, patients with end-stage renal …

Onco-nephrology is a rapidly growing field that has recently garnered significant attention.
Although the risk of developing cancer is reported to be higher in patients with end-stage …